Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Remimazolam Besylate
The First People's Hospital of Lianyungang
Critical Illness; Mechanical Ventilation; Shock
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Crohn Disease
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma
3 trials -
Rituximab
The First People's Hospital of Lianyungang
Refractory Myasthenia Gravis
1 trial -
Robotic Gastrectomy
The First People's Hospital of Lianyungang
Gastric Cancer (GC)
1 trial -
S-1 therapy
The First People's Hospital of Lianyungang
Carcinoma, Non-Small-Cell Lung
1 trial -
Sorafenib
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Suxiao Jiuxin Pill
The First People's Hospital of Lianyungang
Acute Mountain Sickness
1 trial -
TNK-tPA
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
The methylprednisolone sodium succinate
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
Tiaoshen Anti-cancer Granules
The First People's Hospital of Lianyungang
Ovarian Neoplasms Malignant
1 trial -
Tinidazole oral microneedle patch
The First People's Hospital of Lianyungang
Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Rectal Neoplasms
1 trial -
Tislelizumab + SOX Chemotherapy
The First People's Hospital of Lianyungang
Gastric Cancer Stage III
1 trial -
Tranexamic acid
The First People's Hospital of Lianyungang
Hemorrhage, Postpartum
1 trial -
Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.
The First People's Hospital of Lianyungang
Post-stroke Epilepsy
1 trial -
Triptorelin for Injection
The First People's Hospital of Lianyungang
Ovarian Hyperstimulation Syndrome
1 trial -
Trophic enteral feeding combined with supplemental parenteral nutrition
The First People's Hospital of Lianyungang
Severe Stroke
1 trial -
Two Anti-angiogenesis Drugs(Endostar and Thalidomide)
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
Tyrosine kinase inhibitor (TKIs)
The First People's Hospital of Lianyungang
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
1 trial -
UDCA
The First People's Hospital of Lianyungang
Diabetes Mellitus
1 trial -
Ustekinumab
The First People's Hospital of Lianyungang
Crohn Disease
1 trial -
Venetoclax
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Venetoclax in combination with fludarabine and melphalan
The First People's Hospital of Lianyungang
Venentoclax
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources